Zhengye Biotechnology (ZYBT) - Amount of Cash per Share

Zhengye Biotechnology - graphic logo of issuer ZYBT

A steady capital inflow from the sale of veterinary products supports current R&D expenditures for Zhengye Biotechnology (ZYBT). An analysis of the issuer's cash per share confirms financial resilience, where the 0.10 mark indicates the level of the assets' defensive barrier. Such stability is based on leadership within the Chinese biologicals sector and the flawless trust of farmers in the quality of Zhengye Biotechnology vaccines.

Zhengye Biotechnology - ZYBT Cash Funds per Share (period 01/08/2025 - 11/20/2026)

Analytical breakdowns for Zhengye Biotechnology

- stock value and consensus price forecast:
- market capitalization indicators:
- cash availability and cash flow indicators:
Summary company analysis:ZYBT - Zhengye Biotechnology
Brand item of Zhengye Bio

This metric reflects net liquidity per ordinary share, allowing for an assessment of the company's real cash reserves net of liabilities. For Zhengye Biotechnology (ZYBT), amid expansion into the growing Asian veterinary drug market, monitoring cash per share helps distinguish strategic reserves for business scaling from inefficient capital accumulation, eliminating distortions caused by infrequent quarterly reporting.